{"id":538425,"date":"2021-09-15T07:33:25","date_gmt":"2021-09-15T11:33:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/"},"modified":"2021-09-15T07:33:25","modified_gmt":"2021-09-15T11:33:25","slug":"revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/","title":{"rendered":"Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit"},"content":{"rendered":"

\nCompany\u2019s Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs
\n<\/h2>\n
\n

REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the upcoming 3rd<\/sup> Annual RAS-Targeted Drug Development Summit being held September 21-23, 2021. Steve Kelsey, M.D., president, research and development, will serve as chairperson for one of the conference\u2019s scientific tracks and moderate a panel discussion during the virtual event. In addition, Jan Smith, Ph.D., senior vice president, biology and Bob Nichols, Ph.D., project lead for RMC-6291, the company\u2019s development-stage KRASG12C<\/sup>(ON) inhibitor, will each deliver a scientific presentation as part of the conference.<\/p>\n

Details of Revolution Medicines\u2019 participation in the 3rd<\/sup> Annual RAS-Targeted Drug Development Summit are as follows:<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
\n Presentations:<\/u>
\n <\/strong>
\n \n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Title:<\/strong>\n <\/td>\nTargeting KRASG12C<\/sup>(ON) & Potential Application to Overcoming Drug Resistance in RAS-Addicted Tumors<\/td>\n<\/tr>\n
\n Presenter:<\/strong>\n <\/td>\nBob Nichols, Ph.D., project lead for RMC-6291<\/td>\n<\/tr>\n
\n Date:<\/strong>\n <\/td>\nWednesday, September 22, 2021<\/td>\n<\/tr>\n
\n Time:<\/strong>\n <\/td>\n11:55 a.m. Eastern<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Title:<\/strong>\n <\/td>\nCombination Strategies to Defeat RAS-Addicted Cancers<\/td>\n<\/tr>\n
\n Presenter:<\/strong>\n <\/td>\nJan Smith, Ph.D., senior vice president, biology<\/td>\n<\/tr>\n
\n Date:<\/strong>\n <\/td>\nWednesday, September 22, 2021<\/td>\n<\/tr>\n
\n Time:<\/strong>\n <\/td>\n2:00 p.m. Eastern<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n
\n Panel Discussion:<\/u>
\n <\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Title:<\/strong>\n <\/td>\nOn the Horizon \u2013 Discussing the Post-Approval Landscape for Successful RAS Drugs Beyond AMG510<\/td>\n<\/tr>\n
\n Moderator:<\/strong>\n <\/td>\nSteve Kelsey, M.D., president, research and development<\/td>\n<\/tr>\n
\n Date:<\/strong>\n <\/td>\nThursday, September 23, 2021<\/td>\n<\/tr>\n
\n Time:<\/strong>\n <\/td>\n4:15 p.m. Eastern<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n
\n Scientific Track:<\/u>
\n <\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Title:<\/strong>\n <\/td>\nValidating Robust Combination Strategies<\/td>\n<\/tr>\n
\n Chairperson:<\/strong>\n <\/td>\nSteve Kelsey, M.D., president, research and development<\/td>\n<\/tr>\n
\n Date\/Time:<\/strong>\n <\/td>\nWednesday, September 22, 2021; 11:30 a.m. \u2013 5:00 p.m. Eastern
Thursday, September 23, 2021; 11:00 a.m. \u2013 12:30 p.m. Eastern<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

Additional information on the Digital RAS-Targeted Drug Discovery Summit is available through the conference website at https:\/\/ras-drugdevelopment.com\/<\/a><\/p>\n

\n About Revolution Medicines, Inc.<\/strong>\n <\/p>\n

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.<\/p>\n

The company\u2019s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

For Investors:
Vida Strategic Partners<\/strong>
Stephanie Diaz
415-675-7401
sdiaz@vidasp.com<\/a><\/p>\n

For Media:
Vida Strategic Partners<\/strong>
Tim Brons
415-675-7402
tbrons@vidasp.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Company\u2019s Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the upcoming 3rd Annual RAS-Targeted Drug Development Summit being held September 21-23, 2021. Steve Kelsey, M.D., president, research and development, will serve as chairperson for one of the conference\u2019s scientific tracks and moderate a panel discussion during the virtual event. In addition, Jan Smith, Ph.D., senior vice president, biology and Bob Nichols, Ph.D., project lead for RMC-6291, the company\u2019s development-stage KRASG12C(ON) inhibitor, will each deliver a … <\/p>\n

Continue reading “Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-538425","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRevolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company\u2019s Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the upcoming 3rd Annual RAS-Targeted Drug Development Summit being held September 21-23, 2021. Steve Kelsey, M.D., president, research and development, will serve as chairperson for one of the conference\u2019s scientific tracks and moderate a panel discussion during the virtual event. In addition, Jan Smith, Ph.D., senior vice president, biology and Bob Nichols, Ph.D., project lead for RMC-6291, the company\u2019s development-stage KRASG12C(ON) inhibitor, will each deliver a … Continue reading "Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-15T11:33:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjAxNyM0NDA1MDEyIzIxOTQwMzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit\",\"datePublished\":\"2021-09-15T11:33:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\\\/\"},\"wordCount\":439,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNjAxNyM0NDA1MDEyIzIxOTQwMzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\\\/\",\"name\":\"Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNjAxNyM0NDA1MDEyIzIxOTQwMzQ=\",\"datePublished\":\"2021-09-15T11:33:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNjAxNyM0NDA1MDEyIzIxOTQwMzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNjAxNyM0NDA1MDEyIzIxOTQwMzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/","og_locale":"en_US","og_type":"article","og_title":"Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit - Market Newsdesk","og_description":"Company\u2019s Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the upcoming 3rd Annual RAS-Targeted Drug Development Summit being held September 21-23, 2021. Steve Kelsey, M.D., president, research and development, will serve as chairperson for one of the conference\u2019s scientific tracks and moderate a panel discussion during the virtual event. In addition, Jan Smith, Ph.D., senior vice president, biology and Bob Nichols, Ph.D., project lead for RMC-6291, the company\u2019s development-stage KRASG12C(ON) inhibitor, will each deliver a … Continue reading \"Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-15T11:33:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjAxNyM0NDA1MDEyIzIxOTQwMzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit","datePublished":"2021-09-15T11:33:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/"},"wordCount":439,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjAxNyM0NDA1MDEyIzIxOTQwMzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/","name":"Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjAxNyM0NDA1MDEyIzIxOTQwMzQ=","datePublished":"2021-09-15T11:33:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjAxNyM0NDA1MDEyIzIxOTQwMzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjAxNyM0NDA1MDEyIzIxOTQwMzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-participate-in-3rd-annual-ras-targeted-drug-development-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/538425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=538425"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/538425\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=538425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=538425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=538425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}